Paper42928005PubMed
[KASID Guidelines for the Medical Treatment of Crohn's Disease: 2026].
Shin SY and 22 others. Korean J Gastroenterol, 2026.
Cite this record
ConductScience Library. [KASID Guidelines for the Medical Treatment of Crohn's Disease: 2026]. Papers, record 42928005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42928005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- [KASID Guidelines for the Medical Treatment of Crohn's Disease: 2026].
- Journal
- Korean J Gastroenterol
- Year
- 2026
- Publication types
- English Abstract, Journal Article, Practice Guideline, Review
- Revised in PubMed
- 2026-10-30
Source PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Crohn Disease | Major topic |
| Humans | |
| Biosimilar Pharmaceuticals | |
| Immunomodulating Agents |
Source PubMed
References184
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25993693 | Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study. | Inflamm Bowel Dis | 2015 | https://conductscience.org/library/papers/25993693 | PubMed |
| 2 | 37089065 | Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study. | Aliment Pharmacol Ther | 2023 | https://conductscience.org/library/papers/37089065 | PubMed |
| 3 | 32648579 | Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. | J Crohns Colitis | 2020 | https://conductscience.org/library/papers/32648579 | PubMed |
| 4 | 40717455 | Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. | Aliment Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40717455 | PubMed |
| 5 | 32881046 | Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease. | J Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/32881046 | PubMed |
| 6 | 40243842 | Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). | J Crohns Colitis | 2025 | https://conductscience.org/library/papers/40243842 | PubMed |
| 7 | 29363534 | Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. | Gut | 2019 | https://conductscience.org/library/papers/29363534 | PubMed |
| 8 | 31892912 | Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. | Gastroenterol Hepatol (N Y) | 2019 | https://conductscience.org/library/papers/31892912 | PubMed |
| 9 | 30656288 | Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration. | J Can Assoc Gastroenterol | 2018 | https://conductscience.org/library/papers/30656288 | PubMed |
| 10 | 32733600 | Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. | Ther Adv Gastroenterol | 2020 | https://conductscience.org/library/papers/32733600 | PubMed |
| 11 | 35987302 | Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. | Clin Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/35987302 | PubMed |
| 12 | 27713072 | GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. | J Clin Epidemiol | 2017 | https://conductscience.org/library/papers/27713072 | PubMed |
| 13 | 36245343 | Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease. | Intest Res | 2023 | https://conductscience.org/library/papers/36245343 | PubMed |
| 14 | 40255145 | 5-Aminosalicylates for non-surgical patients with active or quiescent Crohn's disease: an overview of systematic reviews (umbrella review). | J Crohns Colitis | 2025 | https://conductscience.org/library/papers/40255145 | PubMed |
| 15 | 20393175 | Infliximab, azathioprine, or combination therapy for Crohn's disease. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20393175 | PubMed |
| 16 | 10228190 | Infliximab for the treatment of fistulas in patients with Crohn's disease. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10228190 | PubMed |
| 17 | 38402895 | A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. | Lancet Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38402895 | PubMed |
| 18 | 29471381 | Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. | J Crohns Colitis | 2018 | https://conductscience.org/library/papers/29471381 | PubMed |
| 19 | 21070781 | Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. | Gastroenterology | 2011 | https://conductscience.org/library/papers/21070781 | PubMed |
| 20 | 4143532 | Controlled trial of azathioprine in Crohn's disease. | Lancet | 1971 | https://conductscience.org/library/papers/4143532 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42928005
GET https://conductscience.org/api/papers/v1/42928005/authors?page=2